Die Onkologie pp 1677-1696 | Cite as

Nephroblastom (Wilms-Tumor)

Zusammenfassung

Der Wilms-Tumor bzw. das Nephroblastom wurde erstmals 1814 von Rance als renale Neoplasie klassifiziert (Rance 1814) und 1899 von dem Chirurgen Max Wilms in einer 90-seitigen Monographie „Die Mischgeschwülste der Niere“ ausführlich beschrieben (Wilms 1899). Der ehemals immer zum Tod führende Tumor gilt heute als das Paradebeispiel einer heilbaren malignen Erkrankung. Die Verbesserungen in der Behandlung des Nephroblastoms fußen insbesondere auf den Fortschritten in der Chirurgie, der Radiotherapie und in der Entwicklung effektiver Chemotherapien. Interdisziplinäre Zusammenarbeit der beteiligten Fachdisziplinen (Radiodiagnostiker, Chirurgen, Radiotherapeuten, Pathologen, Pädiater) und prospektive randomisierte Therapiestudien haben einen erheblichen Beitrag zu diesem Erfolg geleistet.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Babyn P, Owens C, Gyepes M, D’Angio GJ (1995) Imaging patients with Wilms’Tumor. Hematol Oncol Clin N Am 9: 1217–1252Google Scholar
  2. Barbaux S, Niaudet P, Gubler MC et al. (1997) Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 17: 467–470PubMedCrossRefGoogle Scholar
  3. Bardeesy N, Falkhof D, Petruzzi MJ et al. (1994) Anaplastic Wilms’tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7: 91–97PubMedCrossRefGoogle Scholar
  4. Beckwith JB (1982) Histopathological aspects of renal tumors in children. In:Alan R (ed), Renal tumors. Proc First International Symposium an KidneyTumors. Liss, New York, pp 1–14Google Scholar
  5. Beckwith JB, Kiviat NB, Bonadio JF (1990) Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms’ tumor. Pediatr Pathol 10: 1–36PubMedCrossRefGoogle Scholar
  6. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59: 74–79PubMedGoogle Scholar
  7. Birch JM, Breslow M (1995) Epidemiologic features of Wilms Tumor. Hematol Oncol Clin N Am 9: 1157–1178Google Scholar
  8. Breslow N, Olsham A, Beckwith JB, Green DM (1993) Epidemiology of Wilms Tumor. MPO 21: 172–181CrossRefGoogle Scholar
  9. Breslow NE, Norkool PA, Olshan A, Evans A, D’Angio G (1988) Second malignant neoplasm in survivors of Wilms’tumor: a report from the national Wilms’tumor study. J Natl Cancer Inst 80: 592–595PubMedCrossRefGoogle Scholar
  10. Bürger D, Feickert HJ, Mildenberger H (1986) Current status of nephroblastoma treatment. Monogr Paediatr 18: 224–242Google Scholar
  11. Call K, Glaser TM, Ito CY et al. (1990) Isolation and characterization of a zinc finger polypeptide gene at human chromosome 11 Wilms’tumor locus. Cel l 60: 509–520CrossRefGoogle Scholar
  12. Clericuzio CL, Johnson C (1995) Screening for Wilms tumor in highrisk individuals. Hematol Oncol Clin N Am 9: 1253–1265Google Scholar
  13. Coppes MJ, de Kraker J, van Dijken PJ et al. (1989) Bilateral Wilms’ tumor: Long term survival and some epidemiological features. J Clin Onco 17: 310–315Google Scholar
  14. Coppes MJ, Zandvoort SWH, Sparling CR, Poon AO, Weitzman S, Blanchette VS (1992) Acquired von Willebrand disease in Wilms’tumor patients. J Clin Oncol 10: 422–427PubMedGoogle Scholar
  15. Couillin P, Azoulay M, Henry I et al. (1989) Characterization of a panel of somatic cell hybrids for subregional mapping along 11p and within band 11p13. Hum Genet 82: 171–178PubMedCrossRefGoogle Scholar
  16. Cowell JK, Wadey RB, Buckle BB, Pritchard J (1989)The aniridia Wilms’tumor association:molecular and genetic analysis of chromosome deletions an the short arm of chromosome 11. Hum Genet 82: 123–126Google Scholar
  17. Cui H, Hedborg F, He Letal. (1997) Inactivation of H19, an imprinted and putative tumor repressor gene is a preneoplastic event during Wilms’tumorigenesis. Cancer Res 57: 4469–4473PubMedGoogle Scholar
  18. D’Angio GJ, Evans A, Breslow N et al. (1976) The treatment of Wilms’tumor. Results of the National Wilms Tumor Study. Cancer 38: 633–646PubMedCrossRefGoogle Scholar
  19. D’Angio GJ, Evans A, Breslow N et al. (1981) The treatment of Wilms’tumor. Results of the Second National Wilms’Tumor Study. Cancer 47: 2302–2311PubMedCrossRefGoogle Scholar
  20. D’Angio GJ (1987) Unexpected toxicity encountered in the National Wilms’Tumor study. Cancer Treat Rep 71: 993PubMedGoogle Scholar
  21. D’Angio GJ, Breslow N, Beckwith B et al. (1989) Treatment of Wilms’ tumor. Results of the Third National Wilms’Tumor Study. Cancer 64: 349–360PubMedCrossRefGoogle Scholar
  22. Dao D, Walsh CP, Yuan L et al. (1999) Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms’tumorigenesis and methylation hyper-dependence of H19 imprinting. Hum Mol Genet 8: 1337–1352PubMedCrossRefGoogle Scholar
  23. Davies R, Moore A, Schedl A et al. (1999) Multiple roles for the Wilms’tumor suppressor, WT1. Cancer Res 59: 1747–1751Google Scholar
  24. Delemarre JFM, Sandstedt B, Harms D, Boccon-Gibod L, Vujanic (1996) Letter to the Editor:The New STOP ( Stockholm) working classification of renal tumours of childhood. Med Ped Oncology 26: 145–146Google Scholar
  25. de Kraker J, Lemerle J, Voute PA, Zucker JM, Tournade MF, Carli M (1990) Wilms’ tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. J Clin Onco18: 1187–1190Google Scholar
  26. de Kraker J (2000) Minutes of the Wilms’tumour trial and study Committee Meeting. Amsterdam 3. 3. 2000Google Scholar
  27. Flentje M, Weirich A, Potter R, Ludwig R (1994) Hepatotoxicity in irradiated nephroblastoma patients during postoperative treatment according to SIOP9/GPOH. Radiother Onco 131: 222–228CrossRefGoogle Scholar
  28. Francke U, Holmes LB, Atkins L, Riccardi VM (1979) AniridiaWilms’ tumor association: Evidence for specific deletion of 11p13. Cytogenet Cell Genet 24: 185–192PubMedCrossRefGoogle Scholar
  29. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP (1990) Homozygous deletion in Wilms’tumour of a zinc-finger gene identified by chromosome jumping. Nature 343: 774–778PubMedCrossRefGoogle Scholar
  30. Gessler M, König A, Bruns GAP (1992) The genomic organization and expression of the WT1 gene. Genomics 12: 807–813PubMedCrossRefGoogle Scholar
  31. Graf N, Weirich A (1996) Wilms’tumour — the state of the art. Onkologie 19: 36–42CrossRefGoogle Scholar
  32. Graf N, Tournade MF, de Kraker J (2000) The role of preoperative chemotherapy in the management of Wilms Tumor —The STOP Studies. Urol Clin North Am 27: 443–454PubMedCrossRefGoogle Scholar
  33. Green DM, Thomas RM, Shochat S (1995) The treatment of Wilms tumor. Hematol Oncol Clin N Am 9: 1267–1274Google Scholar
  34. Green DM, Breslow NE, Beckwith JB et al. (1998) Effect of duration of treatment an treatment outcome and cost of treatment for Wilms’ tumor: a report from the National Wilms’Tumor Study Group. J Clin Oncol 16: 3744–3751PubMedGoogle Scholar
  35. Green DM, Breslow NE, Beckwith JB et al. (2001) Treatment with nephrectomy only for small, stage I/favorable histology Wilms’tumor: a report from the National Wilms’Tumor Study Group. J Clin Oncol 19: 3719–724PubMedGoogle Scholar
  36. Grundy P, Koufos A, Morgan K, Li FP, Meadows AT, Cavenee WK (1988) Familial predisposition to Wilms tumour does not map to the short arm of chromosome 11. Nature 336: 374–376PubMedCrossRefGoogle Scholar
  37. Grundy P, Coppes MJ, Haber D (1995) Molecular genetics of Wilms tumor. Hematol Oncol Clin N Am 9: 1201–1215Google Scholar
  38. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC (1994) Loss of heterozygosity for chromosomas 16q and 1 p in Wilms’tumors predicts an adverse outcome. Cancer Res 54: 2331–2333PubMedGoogle Scholar
  39. Grunning KB, Cohn SL, Tomlinsen GE, Strong LC, Huff V (1996) Analysis of possible abnormal WT1 RNA processing in primary Wilms tumors. Oncogene 13: 1179–1185Google Scholar
  40. Gutjahr P, Kaatsch P, Spaar HJ et al. (1990) Klinik, Therapie and Prognose bei 373 Kindern mit Wilms-Tumoren–Ergebnisse der bundesweiten Studie 1980–1988. Akt Uro121: 132–141Google Scholar
  41. Haaf HG, Kaatsch P, Michaelis J (1995) Jahresbericht 1995 des Deutschen Kinderkrebsregisters, MainzGoogle Scholar
  42. Haber DA, Buckler AJ, Glaser T et al. (1990) An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms tumor. Cell 61: 1257–1269PubMedCrossRefGoogle Scholar
  43. Heidemann RL, Haase GM, Foley ChL, Wilson HL, Bailey WC (1985) Nephroblastomatosis and Wilms’ Tumor. Clinical experience and management of seven patients. Cancer 55: 1446–1451CrossRefGoogle Scholar
  44. Hempel L, Kremens B, Weirich A, Graf N, Zintl F, Ludwig R (1996) High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma intially treated according to the SIOP9/GPOH trial and study. Klin Pädiatr 208: 186–189PubMedCrossRefGoogle Scholar
  45. Hennigar RA, Othersen HB, Garvin AJ (1989) Clinicopathologic features of nephroblastomatosis. Urology 33: 259–270PubMedCrossRefGoogle Scholar
  46. Henry I, Grandjouan I, Couillin Pet al. (1989) Tumor-specific loss of 11p15. 5 alleles in del 11p13 Wilms tumor and in familial adrenocortical carcinoma. Proc Natl Acad Sci USA 86: 3247–3251Google Scholar
  47. HGM 10 Human Gene Mapping 10 (1989) 10th international workshop an human gene mapping. Cytogenet Cell Genet 51:1–4Google Scholar
  48. Hou LT, Holman RL (1961) Bilateral nephroblastomatosis in a premature infant. J Pathol Bacteriol 82: 249–255PubMedCrossRefGoogle Scholar
  49. HuffV, Compton DA, Chao LY, Strong LC, Geiser CF, Saunders GF (1988) Lack of linkage of familial Wilms’ tumour to chromosomal band 11p13. Nature 336: 377–378CrossRefGoogle Scholar
  50. HuffV (1998) Wilms Tumor genetics. Am J Med Genet 79: 260–267CrossRefGoogle Scholar
  51. Klamt B, Schulze M, Thate C et al. (1998) Allele loss in Wilms tumors of Chromosome arms 1 Iq, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer 22: 287–294PubMedCrossRefGoogle Scholar
  52. Koufos A, Grundy P, Morgan K et al. (1989) Familial Wiedemann-Beckwith syndrome and a second Wilms’ tumor locus map to 11p15. 5. Am J Hum Genet 44: 711–719PubMedGoogle Scholar
  53. Kraker de J, Weitzman S, Voüte PA (1995) Preoperative strategies in the management of Wilms Tumor. Hematol Oncol Clin N Am 9: 12751285Google Scholar
  54. Lamond Al (1995) RNA processing. Wilms’ tumour-the splicing connection? Current Biology 5: 862–865CrossRefGoogle Scholar
  55. Lemerle J, Voûte PA, Tournade MF et al. (1976) Pre-operative versus postoperative radiotherapy, single versus multiple courses of Actinomycin D in the treatment of Wilms’ tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (SIOP). Cancer 38: 647–654PubMedCrossRefGoogle Scholar
  56. Lemerle J, Tournade ME, Voute PA (1981) Effectiveness of preoperative radiotherapy (PDXRT) and/or chemotherapy (POC) in Wilms’ tumor (WT). Proc Annu Meet Am Soc Clin Oncol 22: C294Google Scholar
  57. Lemerle J, Voûte PA, Tournade ME et al. (1983) Effectiveness of preoperative chemotherapy in Wilms’ tumor: Results of an International Society of Pediatric Oncology (STOP) clinical trial. J Clin Oncol 1: 604–609PubMedGoogle Scholar
  58. Li M, Squire JA, Weksberg R (1998) Molecular genetics of Wiedemann-Beckwith syndrome. Am J Med Genetics 79: 253–259CrossRefGoogle Scholar
  59. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ (1995) Expression, promotor usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 11: 221–229PubMedGoogle Scholar
  60. Little M, Holmes G, Walsh P (1999) WT1: what has the last decade told us. Bio Essay 21: 191–202Google Scholar
  61. Ludwig R, Weirich A, Pötter R et al. (1992) Präoperative Chemotherapie des Nephroblastoms. Klin Pädiatr 204: 204–213PubMedCrossRefGoogle Scholar
  62. Ludwig R, Weirich A, Hofmann WJ, Waldherr R (1992) Veno-occlusive disease (VOD) as hepatotoxic side effect of the nephroblastoma SIOP-9 treatment protocol:preliminary results of the german group. Med Ped Oncol 20: 434Google Scholar
  63. Ludwig R, Weirich A, Bürger D et al. (1997) Durchführung eines neuen Therapiekonzeptes für Nephroblastome im Bereich der Gesellschaft für Pädiatrische Onkologie and Hämatologie–SIOP 9/GPOH. Mschr Kinderhlkd 145: 128–135CrossRefGoogle Scholar
  64. Maher ER, Reik W (2000) Beckwith-Wiedemann syndrome: imprinting in clusters revisited. J Clin Invest 105: 247–252PubMedCrossRefGoogle Scholar
  65. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher FJ (1991) Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 253: 1550–1553PubMedCrossRefGoogle Scholar
  66. Malik K, Salpekar A, Hancock A, Moorwood K, Jackson S, Charles A (2000) Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms’ tumor. Cancer Res 60: 2356–2360PubMedGoogle Scholar
  67. Malkin D, Sexsmith E, Yeger H, Williams BRG (1994) Mutations of the p53 Tumor suppressor gene occur infrequently in Wilms’Tumor. Cancer Res 54: 2077–2079PubMedGoogle Scholar
  68. Maw MA, Grundy PE, Millow U et al. (1992) A third Wilms’ tumor locus an chromosome 16q. Cancer Res 52: 3094–3098PubMedGoogle Scholar
  69. Miller RW, Fraumeni JR, Manning MD (1964) Association of Wilms tumor with aniridia, hemihypertrophy and other congenital anomalies. N Engl J Med 270: 922–927PubMedCrossRefGoogle Scholar
  70. Miozzo M, Perotti D, Minoletti F et al. (1996) Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors. Genomics 37: 310–315PubMedCrossRefGoogle Scholar
  71. Miser JS, Tournade MF (1995) The management of relapsed Wilms tumor. Hematol Oncol Clin N Am 9: 1287–1302Google Scholar
  72. Oberlin O, Tournade MF, Daltroff G et al. (1989) Hepatic toxicity compatible with veno-occlusive disease (VOD) after actinomycin D in non-irradi-ated Wilms’tumors. Med Ped Oncol 17: 317Google Scholar
  73. Patek CE, Little MH, Fleming S et al. (1999) A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. Proc Natl Acad Sci 96: 2931–2936PubMedCrossRefGoogle Scholar
  74. Pein F, Michon J, Valteau-Couanet D et al. (1998) High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue pediatric high-risk recurrent Wilms’ tumor: a French Society of Pediatric Oncology study. J Clin Oncol 16: 3295–3301PubMedGoogle Scholar
  75. Pfeil J, Niethard FV, Oppermann HC, Scheibe P, Willich E (1986) Strahlenschäden derWirbelsäule nach Radiatio wegen einesWilms-Tumors im Kleinkindesalter. Verlaufsuntersuchung bei 82 Kindern. Orthopäd Praxis 22: 863–870Google Scholar
  76. Ping AJ, Reeve AE, Law DJ, Young MR, Boehnke M, Feinberg AP (1989) Genetic linkage of Beckwith-Wiedemann syndrome to 11 p15. Am J Hum Genet 44: 720–723PubMedGoogle Scholar
  77. Raine J, Bowman A, Wallendszus K, Pritchard J (1991) Hepatopathythrombocytopenia syndrome–A complication ofdactinomycin therapy for Wilms’ Tumor: A report from the United Kingdom Children Cancer Study Group. J Clin Oncol 9: 268–273PubMedGoogle Scholar
  78. Rahman N, Arbour L, Tonin P et al. (1996) Evidence for a familial Wilms’ tumour gene (FWT1) an chromosome 17812-q21. Nat Genet 13: 461–463PubMedCrossRefGoogle Scholar
  79. Rahman N, Abidi F, Ford D et al. (1998) Confirmation of FWT1 as a Wilms’ tumour susceptibility gene and phenotypic characteristics of Wilms’ tumour attributable to FWT1. Hum Genet 103: 547–556PubMedCrossRefGoogle Scholar
  80. RanceTF (1814) Case of fungus haematodes of the kidneys. Med Phys J 32: 19Google Scholar
  81. Rauscher FJ, Morris JF, Tournay OE, Cook DM, Curran T (1990) Binding of the Wilms tumor zinc fmger protein to the EGR-1 consensus sequence. Science 250: 1259–1262PubMedCrossRefGoogle Scholar
  82. Reinhard H, Aliani S, Weirich A, Harms D, Graf N (2000) Adults with nephroblastoma treated according to the STOP 93–01/GPOH protocol. Med Ped Onco 135: P183Google Scholar
  83. Riccardi VM, Sujansky E, Smith AC, Francke V (1978) Chromosomal imbalance in the aniridia-Wilms’tumor association 11p interstitial deletion. Pediatrics 61: 604–610PubMedGoogle Scholar
  84. Rieden K, Weirich A, Träger J, Gamroth AH, Raschke K, Ludwig R (1993) Accuracy of diagnostic imaging in nephroblastoma before preoperative chemotherapy. Eur Radio 3: 115–122CrossRefGoogle Scholar
  85. Ritchey M, Panayotis PK, Breslow N, Etzioni R, Evans I, Haase GM, D’Angio GJ (1992) Surgical complications after nephrectomy for Wilms’ tumor. Surg Gynecol Obstetr 175: 507–514Google Scholar
  86. Ritchey ML, Coppes MJ (1995) The management of synchronous bilateral Wilms Tumor. Hematol Oncol Clin N Am 9: 1303–1315Google Scholar
  87. Roth H, Weirich A, Ludwig R, Daum R, Zimmermann H (1996) Die Resektion des Nephroblastoms: Probleme and Komplikationen — Auswertungen zur Nephroblastomstudie STOP 9/GPOH. Langenbecks Arch Chir [Suppl] 113: 1078–1083Google Scholar
  88. Schmidt D, Beckwith JB (1995) Histopathology of childhood renal tumors. Hematol Oncol Clin N Am 9: 1179–1200Google Scholar
  89. Schmidt D, Kramer A, Leuschner I, Weirich A, Ludwig R, Harms D (1992) Tumor regression in nephroblastoma after preoperative chemotherapy according to STOP 9/GPO. Morphological features and relationship to prognosis. Med Ped Onco 120: 433Google Scholar
  90. Schnoeder WT, Chao LY, Dao DD et al. (1987) Nonrandom loss of matemal chromosome 11 alleles in Wilms tumors. Am J Hum Gent 40: 413–420Google Scholar
  91. Schumacher V, Schneider S, Figge A et al. (1997) Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal predominant histology. Proc Natl Acad Sci 94: 3972–3977PubMedCrossRefGoogle Scholar
  92. Schwartz CE, Haber DE, Stanton VP, Strong LC, Skolnick MH, Housman DE (1991) Familial predisposition to Wilms tumor does not segregate with the WT1 gene. Genomics 10: 927–930PubMedCrossRefGoogle Scholar
  93. Smith SI, Down M, Boyd AW, Li CL (2000) Expression of the Wilms’Tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C. B-17 scid/scid Mice. Cancer Res 60: 808–814PubMedGoogle Scholar
  94. Steenman M, Westerveld A, Mannens M (2000) Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer 28: 1–13PubMedCrossRefGoogle Scholar
  95. Stone MS, Beaver BL, Sun CCJ, Hill JL (1990) The nephroblastomatosis com- plex and its relationship to Wilms’tumor. J Ped Surg 25: 933–938CrossRefGoogle Scholar
  96. The National Wilms’Tumor Study Committee (1991) Wilms’Tumor: Status Report, 1990. J Clin Oncol 9: 877–887Google Scholar
  97. Thomas PRM, Tefft M, Compaan PJ, Norkool PP, Breslow NE, D’Angio GJ (1991) Results of two radiation therapy randomisations in the third National Wilms Tumor Study. Cancer 68: 1703–1707PubMedCrossRefGoogle Scholar
  98. Thomas PRM, Griffith KD, Fineberg BB, Perez CA, Land VJ (1983) Late effects of treatment for WilmsTumour. lnti Radiat Oncol Biol Phys 9: 651–657CrossRefGoogle Scholar
  99. Tournade MF, Com-Nougue C, Voûte PA et al. (1993) Results of the sixth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study: A risk-adapted therapeutic approach in Wilms’ Tumor. J Clin Oncol 11: 1014–1023PubMedGoogle Scholar
  100. Tournade MF, Com-Nougue C, de Kraker J et al. (2001) for the International Society of Pediatric Oncology Nephrobalstoma Trial and Study Committee Optimal duration of preoperative therapy in unilateral and nonmetastaticWilms’tumor in children older than 6 months results of the Ninth International Society of Pediatric Oncology Wilms’Tumor Trial and Study. J Clin Oncol 19: 488–500Google Scholar
  101. Van Heyningen, Boyd PA, Seawright A et al. (1985) Molecular analysis of chromosome 11 deletions in aniridia-Wilms tumor syndrome. Proc Natl Acad Sci USA 82: 8592–8596PubMedCrossRefGoogle Scholar
  102. Wilms M (1899) Die Mischgeschwülste der Niere. Arthur Georgi, Leipzig, S 1–90Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • N. Graf

There are no affiliations available

Personalised recommendations